Adjuvant Pancreatic Cancer Management: Towards New Perspectives in 2021
UMR9020-UMR-S 1277 Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, University of Lille, CNRS, Inserm, CHU Lille, Institut Pasteur de Lille, F-59000 Lille, France
Medical Oncology Department, CHU Lille, University of Lille, F-59000 Lille, France
Department of Digestive Surgery and Transplantation, Lille University Hospital, F-59000 Lille, France
Department of Hepatogastroenterology and GI Oncology, La Pitié-Salpêtrière Hospital, INSERM UMRS 1138, Université de Paris, F-75013 Paris, France
Department of Digestive, Oncological, and Transplant Surgery, Paul Brousse Hospital, Paris-Saclay University, F-94800 Villejuif, France
Department of Digestive Surgery, Rouen University Hospital and Université de Rouen Normandie, F-76100 Rouen, France
Service d’Oncologie Digestive et Médicale, Hôpital Paul Brousse (AP-HP), 12 Avenue Paul Vaillant Couturier, F-94800 Villejuif, France
Author to whom correspondence should be addressed.
Received: 29 November 2020 / Revised: 18 December 2020 / Accepted: 19 December 2020 / Published: 21 December 2020
In operated pancreatic cancer patients who are able to begin treatment within 3 months after surgery, adjuvant chemotherapy is currently used to limit disease recurrence but questions remain for the clinician. Recently, modified FOLFIRINOX has become the standard-of-care in the non-Asian population, nevertheless there is still a risk of toxicity and feasibility may be limited in heavily pre-treated patients. Gemcitabine-Nabpaclitaxel, Gemcitabine alone in non-Asian patients are alternatives to be discussed. In Asia, S1-based chemotherapy remains the standard. The aim of this review is to summarize adjuvant management of resected pancreatic cancer and to raise current and future concerns, especially the need for biomarkers and the best holistic care for patients.